Noninvasive prediction of response to cancer therapy using promoter profiling of circulating cell‐free DNA
Main Authors: | Zhi‐Wei Guo, Wei‐Wei Xiao, Xue‐Xi Yang, Xu Yang, Geng‐Xi Cai, Xiao‐Jing Wang, Bo‐Wei Han, Kun Li, Xiang‐Ming Zhai, Fen‐Xia Li, Li‐Min Huang, Ying‐Song Wu, Yuan‐Hong Gao |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-09-01
|
Series: | Clinical and Translational Medicine |
Online Access: | https://doi.org/10.1002/ctm2.174 |
Similar Items
-
Cell-Free Circulating Methylated SEPT9 for Noninvasive Diagnosis and Monitoring of Colorectal Cancer
by: Bo Fu, et al.
Published: (2018-01-01) -
Liquid Biopsy for Cancer: Circulating Tumor Cells, Circulating Free DNA or Exosomes?
by: Wei Zhang, et al.
Published: (2017-02-01) -
Clinical Application Value of Circulating Cell-free DNA in Hepatocellular Carcinoma
by: Yuyuan Zhang, et al.
Published: (2021-09-01) -
Circulating miR-765 and miR-149: Potential Noninvasive Diagnostic Biomarkers for Geriatric Coronary Artery Disease Patients
by: Md Sayed Ali Sheikh, et al.
Published: (2015-01-01) -
Noninvasive Evaluation of the Pathologic Grade of Hepatocellular Carcinoma Using MCF-3DCNN: A Pilot Study
by: Da-wei Yang, et al.
Published: (2019-01-01)